Printer Friendly

PharMerica hopes Omnicare will abandon bid after FTC decision.

M2 PHARMA-January 30, 2012-PharMerica hopes Omnicare will abandon bid after FTC decision(C)2012 M2 COMMUNICATIONS

30 January 2012 - US pharmacy services provider PharMerica Corp (NYSE:PMC) on Monday expressed hope that rival Omnicare Inc (NYSE:OCR) will drop its USD441m (EUR337m) hostile takeover offer for the company after the US Federal Trade Commission (FTC) moved to block it.

"As we have said from the beginning, we believed antitrust clearance would be difficult to achieve and, with that belief now confirmed, we hope that Omnicare will end its hostile pursuit of PharMerica," the latter's CEO, Gregory Weishar, said in a statement.

On Friday, the FTC said a potential deal would harm competition and pave the way for higher drug prices.

In August 2011, Omnicare made a public takeover offer that valued PharMerica at USD716m, including net debt. The bid, however, has been turned down twice by the target company, which also adopted a poison pill to avoid hostile takeovers.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 30, 2012
Words:170
Previous Article:Valeant backs out of plan to buy ISTA Pharma.
Next Article:KineMed to partner with Pfizer to advance new approaches in metabolic disease.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters